Dr. Morris on Mechanism of Action for Radium-223

Michael J. Morris, MD
Published: Wednesday, Jan 27, 2016



Michael Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the mechanism of action for radium-223 dichloride as a treatment for patients with prostate cancer.

The main idea behind a bone-targeting radiopharmaceutical such as radium-223, Morris explains, is that it targets the primary site of metastatic disease. Radium-223 delivers alpha-emitting radiation therapy to the bone, which is where much of prostate cancer localizes to.

Radium-223 has unique characteristics that minimize toxicity and maximizes treatment effect, Morris explains.
 


Michael Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the mechanism of action for radium-223 dichloride as a treatment for patients with prostate cancer.

The main idea behind a bone-targeting radiopharmaceutical such as radium-223, Morris explains, is that it targets the primary site of metastatic disease. Radium-223 delivers alpha-emitting radiation therapy to the bone, which is where much of prostate cancer localizes to.

Radium-223 has unique characteristics that minimize toxicity and maximizes treatment effect, Morris explains.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x